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Background and Purpose: Hypertension is a multifactorial disease, manifested by
vascular dysfunction, increased superoxide production, and perivascular inflamma-
tion. In this study, we have hypothesized that 1,2,3,4,6‐penta‐O‐galloyl‐β‐D‐glucose
(PGG) would inhibit vascular inflammation and protect from vascular dysfunction in
an experimental model of hypertension.
Experimental Approach: PGG was administered to mice every 2 days at a dose of
10 mg·kg−1 i.p during 14 days of Ang II infusion. It was used at a final concentration of
20 μM for in vitro studies in cultured cells.
Key Results: Ang II administration increased leukocyte and T‐cell content in
perivascular adipose tissue (pVAT), and administration of PGG significantly decreased
total leukocyte and T‐cell infiltration in pVAT. This effect was observed in relation to
all T‐cell subsets. PGG also decreased the content of T‐cells bearing CD25, CCR5,
and CD44 receptors and the expression of both monocyte chemoattractant protein
1 (CCL2) in aorta and RANTES (CCL5) in pVAT. PGG administration decreased the
content of TNF+ and IFN‐γ+ CD8 T‐cells and IL‐17A+ CD4+ and CD3+CD4−CD8−
cells. Importantly, these effects of PGG were associated with improved vascular func-
tion and decreased ROS production in the aortas of Ang II‐infused animals indepen-
dently of the BP increase. Mechanistically, PGG (20 μM) directly inhibited CD25
and CCR5 expression in cultured T‐cells. It also decreased the content of IFN‐γ+
CD8+ and CD3+CD4−CD8− cells and IL‐17A+ CD3+CD4−CD8− cells.- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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Conclusion and Implication: PGG may constitute an interesting immunomodulating
strategy in the regulation of vascular dysfunction and hypertension.
LINKED ARTICLES: This article is part of a themed section on Immune Targets in
Hypertension. To view the other articles in this section visit http://onlinelibrary.
wiley.com/doi/10.1111/bph.v176.12/issuetocWhat is already known
• PGG has a wide range of biological activities including
anti‐cancer, anti‐inflammatory, anti‐oxidative effects.
• Little is known about the effect of PGG on hypertension
or vascular inflammation.
What this study adds
• PGG is a candidate for targeting vascular inflammation
and protecting from both oxidative stress and
endothelial dysfunction
• PGG has direct effects on T cell activation and their
perivascular recruitment;
What is the cl inical s ignif icance
• Penta‐O‐galloyl‐β‐D‐glucose may provide opportunities
for the effective treatment of vascular inflammation in
cardiovascular disease and hypertension1 | INTRODUCTION
Vascular inflammation plays a pivotal role in the development and
progression of hypertension and atherosclerosis (Guzik et al., 2007;
Mikolajczyk et al., 2016; Skiba et al., 2017). Recent studies have shown
the involvement of different leukocyte populations such as T‐cells
(Guzik et al., 2007; Mikolajczyk et al., 2016), monocytes (Fujisawa
et al., 2017; Wenzel et al., 2011), macrophages (Chan et al., 2012;
Moore et al., 2015), dendritic cells (Kirabo et al., 2014), and NK cells
(Kossmann et al., 2013) in hypertension (Guzik, Skiba, Touyz, &
Harrison, 2017). Angiotensin II (Ang II) and other pro‐hypertensive
stimuli induce immune cell activation and infiltration to the adventitia
and peri‐adventitial fat (Guzik et al., 2007). These cells can produce a
number of pro‐inflammatory cytokines and chemokines accelerating
inflammation and contributing to vascular disease in hypertension
(Guzik et al., 2007; Kusters, Lutgens, & Seijkens, 2018; Mikolajczyk
et al., 2016). While a myriad of antihypertensive agents is available
(Nguyen, Dominguez, Nguyen, & Gullapalli, 2010), only a few partially
target these inflammatory mechanisms (Hermann & Ruschitzka, 2006).
Current antihypertensive drugs, including those which target the Ang II
system, are effective in controlling BP only in a subset of patients;
however, they do not provide sufficient prevention of target organ
damage in these individuals (Wright et al., 2002). Therefore, a more
comprehensive way of targeting the pathology of hypertension is
required, rather than solely focusing on BP regulation (Williams et al.,
2018). This indicates a need for targeting the pathomechanisms
involved in target organ damage including endothelial dysfunction, oxi-
dative stress, and inflammation. The combination of a current antihy-
pertensive agent with an anti‐inflammatory compound, which targets
the immune system, would be more efficacious in preventing tissue
damage. Suppression of vascular inflammation processes may inhibit
or delay the progression of both hypertension and atherosclerosis.
While systemic immunomodulation using anti‐cytokine treatment has
recently been provided with an important proof‐of‐concept, it is
imperative to identify novel agents that lack strong systemic immuno-
suppressive properties (Ridker et al., 2017). Many natural compounds
derived from plants have shown anti‐inflammatory activity. The
naturally occurring 1,2,3,4,6‐penta‐O‐galloyl‐β‐D‐glucose (PGG) is a
polyphenolic compound highly enriched in Oenothera paradoxa
(Jaszewska, Kosmider, Kiss, & Naruszewicz, 2009; Kiss, Derwinska,
Dawidowska, & Naruszewicz, 2008; Kiss, Filipek, Czerwinska, &
Naruszewicz, 2010). PGG has a wide range of biological activities
including anticancer, anti‐diabetic, anti‐inflammatory, anti‐oxidative,
anti‐allergy, antiviral, and antibacterial effects (Cryan et al., 2013;Zhang, Li, Kim, Hagerman, & Lu, 2009). Little is known about the effect
of PGG on hypertension or vascular inflammation. However, PGG was
shown to reverse cholesterol transport by influencing the expression
of scavenger receptors, suggesting that this polyphenolic component
may represent a novel candidate in the prevention and treatment of
atherosclerosis in humans (Zhao, Haller, & Ritsch, 2015). Therefore,
we aimed to investigate the effect of i.p. PGG administration on
perivascular inflammation, vascular dysfunction, and BP elevation in
an experimental model of Ang II‐dependent hypertension.2 | METHODS
2.1 | Isolation of PGG
PGG was isolated from defatted seed extract of O. paradoxa Hudziok
obtained from Agropharm S. A. (Tuszyn, Poland). One hundred grams
of the seeds were dissolved in water (500 ml) and extracted with ethyl
acetate (3 × 500 ml). Ethyl acetate fractions were dried under vacuum
at 45 °C (giving a residue of ~10 g). The ethyl acetate extract was
further fractionated on a polyamide column (5 cm × 8 cm; particle size
MIKOLAJCZYK ET AL. 1953BJP0.05–0.16 mm, Carl Roth, Germany) and eluted with acetone–water
(7:3 [vol:vol]). One hundred fractions (50 ml each) were collected and
pooled into 1A–6A main fractions based on their polyphenolic profile.
PGG presence was monitored using HPLC. Fraction 5A (675 mg) was
further subfractionated on a Toyopearl HW‐40, fine grade column
(2.5 cm × 35 cm; Tosoh, Japan) using methanol–water (7:3 [vol:vol])
and acetone–water (7:3 [vol:vol]) as eluents. One hundred twenty frac-
tions (10 ml each) were collected. Fractions 111–119 were separated
again, eluted with acetone–water (4:6 [vol:vol]) as eluent to obtain a
compound of purity >95% (390 mg). Chromatograms of crude seed
extract and isolated PGG are presented in Figure S1.2.2 | Characterization of PGG
Off‐white powder; UV, λ max 281 nm; ESI‐MS (negative ion mode) m/z
939.0 [M‐H]−. 1H NMR (MD3OD) glucose moiety: δ 6.46 (1H, d,
J = 8 Hz, H‐1), 6.20 (1H, t, H‐3), 5.85 (1H, m, H‐4), 4.78 (1H, m, H‐5),
4.51 (1H, m, H‐6). Galloyl moieties: δ 7.16, 7.18, 7.23, 7.25, 7.32 (each
2H, s). 13C NMR (MD3OD) glucose moiety: 93.85 (C‐1), 74.45 (C‐5),
74.13 (C‐3), 72.21 (C‐4), 69.82 (C‐2), 63.15 (C‐6). Galloyl moieties:
167.99, 167.35, 167.08, 166.98, 166.28 (carbonyl group signals),
146.63, 146.53, 146.50, 146.44, 146.34 (C‐3, C‐5), 141.00, 140.53,
140.48, 140.27, 140.14 (C‐4), 121.00, 120.31, 120.17, 120.13, 119.62
(C‐1), 110.63, 110.48, 110.42, 110.40, 110.35 (C‐2, C‐6). 1H and 13C
spectra of PGG are presented in Figure S2.2.3 | Animals
Male C57BL/6J (RRID:IMSR_JAX:000664, Bar Harbor, ME, USA) mice
(n = 70) were obtained from Jackson Laboratory. Mice were housed
in controlled 12‐hr light/dark conditions at a constant temperature
(21 ± 3 °C) with ad libitum access to water and standard diet
(rat and mouse no. 1 maintenance diet, Special Diet Services).
Twelve‐week‐old mice underwent either sham (buffer) or Ang II
(490 ng·min−1·kg−1 s.c.) treatment for 14 days, using an osmotic
minipump (Alzet Model 2002, Alzet Corporation, CA) as previously
described (Mikolajczyk et al., 2016). This model of experimental
hypertension in C57BL/6 mice has been well characterized previously
(Guzik et al., 2007). Surgical procedures were performed under general
anaesthesia by using isoflurane (3–5% for induction and 1.5–3% for
maintenance of anaesthesia). PGG 10 mg·kg−1 was injected i.p. every
2 days, as previously described (Huh et al., 2005), starting 1 week
before minipump implantation. PGG was initially dissolved in 96% eth-
anol, and then, 0.9% saline solution was added. The final concentration
of ethanol was 7%. As a placebo, we used 0.9% saline solution with 7%
ethanol. Mice were randomly assigned to either sham or Ang II and
placebo or PGG‐treated groups. Individual mice were assigned numbers
during randomization, therefore, data analysis for all subsequent end-
points was blinded for the treatment assignment groups. Placebo was
administered to control animals. All animals underwent non‐invasive
BP measurement by tail‐cuff plethysmography (Visitech BP 2000 BP
Analysis System), following a 1‐week period of adaptation beforesurgery. Two weeks after minipump implantation, mice were killed,
and aorta and adipose tissue (perivascular and visceral fat) were col-
lected. All animal procedures were approved by Local Ethics Committee
no. 1 in Krakow (Poland; permission no. 16/2012) and by the Home
Office according to the Animals (Scientific Procedures) Act 1986 (pro-
ject licence 60/9021). Animal studies are reported in compliance with
the ARRIVE guidelines (Kilkenny et al., 2010) and with the recommen-
dations made by the British Journal of Pharmacology.2.4 | Vascular reactivity measurements
Isometric tension studies in response to the endothelium‐dependent and
endothelium‐independent vasodilators, ACh and sodium nitroprusside
(SNP), were performed following preconstriction with 1 μM PGF2α in 3‐
to 4‐mm segments of aorta using tissue organ bath system 750TOBS
(Danish Myo Technology) filled with Krebs solution (in mM: 124 NaCl,
4.6 KCl, 2.5 CaCl2, 1.2 MgSO4, 1.2 KH2PO4, 0.01 EDTA, 23 NaHCO3,
and 11 glucose) as reported previously (Mikolajczyk et al., 2016; Siedlinski
et al., 2017). All relaxation responses are expressed as a percentage of the
PGF2α preconstriction. The level of the preconstriction response to PGF2α
was matched between groups to the level of ~80% of maximal constric-
tion. Moreover, PGG did not affect vascular contractility in response to
PGF2α in sham and Ang II‐infused animals.2.5 | Analysis of leukocytes in adipose tissue
For analysis of immune cells in adipose tissue compartments, perivascular
adipose tissue (pVAT) or epididymal (visceral adipose tissue [VAT]) fat was
digested using collagenase type XI (125 U·ml−1), collagenase type IS
(450 U·ml−1), and hyaluronidase IV‐S (60 U·ml−1), which had been dis-
solved in PBS containing calcium and magnesium for 20 min at 37 °C,
with regular agitation. Afterwards, digestion was stopped by addition of
ice‐cold PBS with 20% FBS. The digested tissue was then passed through
a 70‐μm sterile cell strainer (Falcon; BD Biosciences, San Jose, CA) to
yield a single‐cell suspension. Cells were washed twice in PBS with 1%
FBS, resuspended and counted; 0.5 × 106 cells were stained with
fluorophore‐ conjugated monoclonal antibodies: anti‐CD45‐FITC (Clone
30‐F11, BD Biosciences, San Jose, CA, USA), anti‐CD3e‐APC (Clone
145‐2C11, BD Biosciences), anti‐CD4‐APHC7 (Clone GK1.5, BD Biosci-
ences), anti‐CD8a‐PERCP (Clone 53–6.7, BD Biosciences), anti‐CD25‐
PE (Clone PC61.5, eBioscience, San Diego, CA, USA), anti‐CD195‐PE
(Clone HM–CCR5 [7A4], eBioscience), anti‐CD44‐FITC (Clone IM7, BD
Biosciences), anti‐F4/80‐APC (Clone BM8, eBioscience), and anti‐
CD11b‐PE (Clone M1/70, BD Biosciences). After 20 min of staining on
ice, cells were washed twice in PBS with 1% FBS and were analysed using
a BD FACSVerse™ flow cytometer with BD FACSuite™ software (BD
Biosciences). T‐cells were analysed from CD45 positive cells based on
CD3 expression and Side scatter (SSC) signal. Next, within the CD3 gate,
CD4, CD8, and CD3+CD4–CD8– cells were analysed. Macrophages were
defined as the F4/80+CD11b+ population. For each experiment, we per-
formed fluorescence minus one controls for each fluorophore to establish
gates. Dead cells were eliminated from the analysis using BD Horizon™
1954 MIKOLAJCZYK ET AL.BJPFixable Viability Stain 510 (BD Biosciences). Data were analysed by
FlowJo (RRID:SCR_008520) software (FlowJo, Ashland, OR).2.6 | Assessment of intracellular cytokines
Splenocytes (1 × 106 ) were suspended in RPMI 1640 medium (Gibco, Life
Technologies, USA) with 10% FBS, 200‐mM L‐glutamine, and 5 mg ml−1
gentamicin (Sigma‐Aldrich, St. Louis, MO, USA) and were cultured without
or with PGG in a final concentration of 20 μM for 30 min.
In parallel in vivo experiments, leukocytes isolated from pVAT from
sham‐ and Ang II‐infused animals treated with PGG or placebo were stud-
ied. Next, cells were stimulated with leukocyte activation cocktail with BD
Golgi Plug from BD Biosciences for 4 hr at 37 °C in a 5% CO2 humidified
atmosphere. Cells were then washed in PBS with 1% FBS and stained
with monoclonal antibodies: anti‐CD3e‐APC (Clone 145‐2C11, BD Bio-
sciences), anti‐CD4‐APHC7 (Clone GK1.5, BD Biosciences), and anti‐
CD8a‐PERCP (Clone 53–6.7, BD Biosciences). Following washing, fixation
and permeabilization solution (eBioscience) was used for 30 min on ice.
After fixation/permeabilization, cells were washed with permeabilization
buffer (eBioscience) and stained for 20 min with monoclonal antibodies:
anti‐TNF‐PE (Clone MP6‐XT22, BD Biosciences), anti‐IL‐17A‐PE (Clone
eBio17B7, eBioscience), anti‐IL‐17A‐PE‐Cy7 (Clone eBio17B7,
eBioscience), and anti‐IFN‐γ‐FITC (Clone XMG1.2, BD Biosciences). Dead
cells were eliminated from the analysis using BD Horizon™ Fixable Viabil-
ity Stain 510 (BD Biosciences). After additional washes, cells were
analysed using a BD FACSVerse™ flow cytometer.
2.7 | Assessment of T‐cell activation markers in vitro
To evaluate the effect of PGG on the expression of activation markers
on the surface of T‐cells, anti‐CD3 plates were used; 96‐well plates
were coated with anti‐CD3 monoclonal antibodies (Clone 145‐2C11;
Thermo Fisher Scientific, Waltham, MA, USA, Cat# 16‐0031‐81,
RRID:AB_468846). Splenocytes were isolated from C57Bl/6J mice
and then were suspended in RPMI 1640 medium (Gibco, Life Technol-
ogies, Grand Island, NY, USA) with 10% FBS, 200‐mM L‐glutamine,
and 5 mg ml−1 gentamicin (Sigma‐Aldrich) and were cultured with or
without PGG (20 μM) on anti‐CD3‐coated plates for 20 hr. After being
washed in PBS with 1% FBS, they were stained with monoclonal anti-
bodies to identify T‐cell subsets (see above) and with activation marker
monoclonal antibodies: anti‐CD25‐PECY7 (Clone PC61, BD Biosci-
ences), anti‐CD195‐PE (Clone HM‐CCR5 [7A4], eBioscience), and
anti‐CD44‐FITC (Clone IM7, BD Biosciences). Dead cells were elimi-
nated from the analysis using BD Horizon™ Fixable Viability Stain 510
(BDBiosciences). After being stained the cells were washed in PBSwith
1% FBS and were collected using a BD FACSVerse™ flow cytometer.
2.8 | Detection of vascular superoxide production
Aortic segments were equilibrated in oxygenated Krebs‐HEPES (in mM:
NaCl 99.0, NaHCO3 25, KCl 4.7, KH2PO4 1.0, MgSO4 1.2, glucose 11.0,
CaCl 22.5, and Na‐HEPES 20.0) buffer for 15 min at 37 °C. Lucigenin‐
enhanced chemiluminescence (5 μmol·L−1) from intact vessels wasmeasured in buffer (2 ml) containing lucigenin at 37 °C using FB12 Tube
Luminometer (Tritertek Berthold) as previously described (Sagan et al.,
2012; Siedlinski et al., 2017). Superoxide production was expressed as
RLU·s·mg−1 of dry weight as described before (Siedlinski et al., 2017).
2.9 | Cell culture and gene expression measurements
SW 872 cells (ATCC, USA) were grown at 37 °C in a 5% CO2 atmo-
sphere in DMEM supplemented with 10% FBS, 50 U·mL−1 penicillin,
and 50 U·mL−1 streptomycin. For SW872 differentiation to adipo-
cytes, medium was replaced with 10% FBS DMEM with insulin
(1 μM; Cell Applications, San Diego, CA), dexamethasone (0.25 μM;
Sigma‐Aldrich), and IBMX (0.5 mM; Sigma‐Aldrich) for 48 hr. Medium
was replaced with 10% FBS DMEM with insulin (1 μM) for another
48 hr. For the next 4 days, medium was replaced with 10% FBS
DMEM. A day before stimulation, cells were starved in 1% FBS
DMEM and then were stimulated with 50 μM PGG for 24 hr. Total
RNA was obtained from cells using RNeasy Mini Kit (Qiagen, Hilden, Ger-
many) and was measured by Nanodrop 1000 (Thermo Fisher Scientific).
Reverse transcription of 1 μg RNA was performed using High Capacity
cDNA ReverseTranscription Kit (Applied Biosystems). mRNA expressions
of chosen genes were analysed using Fast SYBR® Green Master Mix
(Thermo Fisher Scientific) and designed primers (TNF, forward primer
sequence [5′ → 3′] AGCCCATGTTGTAGCAAACC, reverse primer
sequence [5′ → 3′] TGAGGTACAGGCCCTCTGAT; MCP‐1 (CCL2) for-
ward primer sequence [5′ → 3′] CCCCAGTCACCTGCTGTTAT, reverse
primer sequence [5′ → 3′] AGATCTCCTTGGCCACAATG; RANTES
(CCL5) forward primer sequence [5′ → 3′] CGCTGTCATCCTCATTGCTA,
reverse primer sequence [5′ → 3′] GAGCACTTGCCACTGGTGTA
(Eurofins, Luxembourg). Reactions were prepared and run on 384‐well
plates on the QuantStudio™ 7 Flex Real‐Time PCR System with standard
protocol. Calculations were made using QuantStudio™ Real‐Time PCR
Software. Data were normalized to levels of GAPDH mRNA, and relative
quantification was calculated in comparison to control.2.10 | Gene expression measurements in aortic and
pVAT
Collected tissue was stored in RNAlater stabilization solution (Ambion,
Thermo Fisher Scientific) until RNA isolation. Total RNA was obtained
from cells using RNeasy Mini Kit (Qiagen) and was measured by
Nanodrop 1000 (Thermo Fisher Scientific). Reverse transcription of 1
μg RNA was performed using High Capacity cDNA Reverse Transcrip-
tion Kit (Applied Biosystems, Foster City, CA, USA). mRNA expres-
sions of chosen genes were analysed using TaqMan assays for CCL2
(MCP‐1; Mm00441242_m1), CCL3 (Mm00441259_g1), CCL4
(Mm00443111_m1), and CCL5 (RANTES; Mm01302427_m1). Reac-
tions were prepared and run on 384‐well plates on the QuantStudio™
7 Flex Real‐Time PCR System with standard protocol. Calculations
were made using QuantStudio™ Real‐Time PCR Software. Data were
normalized to levels of Eukaryotic Translation Elongation Factor 2
(EEF2) (Mm05700170_g1) mRNA, and relative quantification was cal-
culated in comparison to control.
FIGURE 1 Effect of 1,2,3,4,6‐penta‐O‐galloyl‐β‐D‐glucose (PGG) on leukocyte infiltration in perivascular adipose tissue (pVAT) during Ang
II‐dependent hypertension. Hypertension was induced by chronic 14‐day infusion of Ang II by osmotic minipump (490 ng·min−1·kg−1), and
leukocytes were isolated from pVAT using enzymatic digestion. (a) Representative flow cytometric analysis of major leukocyte subpopulations in
vascular stromal fraction isolated from pVAT of sham‐ and Ang II‐infused mice treated with PGG or placebo. (b) Effect of Ang II infusion and PGG
administration on absolute numbers of CD45+ total leukocyte content in pVAT expressed per mg of tissue (n = 7). (c) and (d) Effect of Ang II
infusion and PGG administration on CD3+ T‐cells (n = 7) and F4/80+CD11b+ macrophage (n = 5) content respectively. *P < 0.05
MIKOLAJCZYK ET AL. 1955BJP2.11 | Statistical analysis
For comparison of the effects of Ang II and PGG on parameters in dif-
ferent groups of mice, we used two‐way ANOVA with a Bonferroni
post hoc test. For comparisons of vascular function in organ chamber
experiments, repeated‐measures ANOVA was used.
For comparison of two groups, Student's paired t test was used.
Values of P < 0.05 were considered significant. For statistical analysis,
GraphPad PRISM version 6.0c was used. The data and statistical
analysis comply with the recommendations of the British Journal of
Pharmacology on experimental design and analysis in pharmacology.2.12 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org, the com-
mon portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY(Harding et al., 2018), and are permanently archived in the Concise Guide
to PHARMACOLOGY 2017/18 (Alexander et al., 2017).3 | RESULTS
3.1 | Effect of PGG on immune cell infiltration into
pVAT during Ang II‐dependent hypertension
The effect of PGG on leukocyte infiltration into the perivascular tissue
was investigated in a mouse model of experimental hypertension. In
line with previous findings, 14‐day administration of Ang II significantly
increased the content of total leukocytes in pVAT (Figure 1a). Absolute
number of leukocytes significantly increased following Ang II infusion
(730 ± 79 vs. 1640 ± 150 cells·mg−1, P < 0.05; Figure 1b). Importantly,
i.p. administration of PGG (every 2 days) 1 week prior to implantation
of minipumps and during 2 weeks of Ang II infusion significantly
reduced the total number of CD45+ cells in the pVAT in comparison
FIGURE 2 Effect of 1,2,3,4,6‐penta‐O‐galloyl‐β‐D‐glucose (PGG) on T‐cell subset infiltration in perivascular adipose tissue during Ang
II‐dependent hypertension. Absolute number of lymphocytes (a) CD4+, (b) CD8+, and (c) CD3+CD4−CD8− in perivascular adipose tissue
expressed as cells·mg−1 of tissue (n = 7 each). *P < 0.05
1956 MIKOLAJCZYK ET AL.BJPto animals which did not receive this drug (1640 ± 150 vs.
1028 ± 57 cells·mg−1, P < 0.05). In summary, PGG prevented
leukocyte infiltration of pVAT during Ang II infusion (Figure 1b). As
identified before, CD3+ T‐cells were particularly increased following
Ang II administration (158 ± 28 vs. 321 ± 22 cells·mg−1, P < 0.05) and
PGG efficiently prevented this infiltration (321 ± 22 vs. 158 ± 18 cells·mg
−1, P < 0.05; Figure 1a,c). It is important to note that we also observed a sta-
tistically significant change in F4/80 cell content in the placebo group and a
lack of such an increase in PGG‐treated mice, indicating that an effect was
also observed on recruitment of macrophages (Figure 1a,d). Further charac-
terization has shown that all major T‐cell subsets, including CD4+, CD8+,
and CD3+CD4−CD8− cells (Figure 2a–c), were increased in Ang II‐treated
mice, and PGG prevented these increases (Figure 2a–c).
The effect of Ang II infusion on the total number of leukocytes,
T‐cells, and elevation of macrophages was particularly seen in pVAT but
not in VAT (Figure S3a–c). Administration of PGG had no effect on the
number of CD45+, CD3+, and F4/80+CD11b+ cells in VAT (Figure S3).3.2 | Effect of PGG on the content of activated
T‐cells during Ang II‐dependent hypertension
As we had previously identified that the RANTES–CCR5 axis is essential
for activated T‐cell recruitment in hypertension (Mikolajczyk et al., 2016),
we next studied the effects of PGG on the expression of CCR5 and activa-
tion status of infiltrating T‐cells. Ang II‐dependent hypertension was asso-
ciated with an increased number of CCR5 positive (both CD4+ and
CD8+) T‐cells in pVAT (Figure 3a). Additionally, the number ofCD25+CD4+, but not CD25+CD8+ T‐cells, was increased following Ang II
infusion (Figure 3a). This effect was not seen in mice that had received
PGG during Ang II administration (Figure 3a). Administration of PGG during
Ang II‐dependent hypertension significantly decreased the number of
CCR5+CD4+ and CCR5+CD8+ cells (Figure 3a). PGG also efficiently
reduced the content of CD4+ cells bearing CD25 during the development
of hypertension (Figure 3a). Ang II infusion increased the number of CD44+
(both CD4+ and CD8+) T‐cells, and PGG efficiently reduced the content of
these cells when it was administered together with Ang II (Figure 3a).3.3 | PGG exhibits anti‐inflammatory effects in vitro
To investigate the effect of PGG on T‐cell activation in vitro, we
cultured freshly isolated splenocytes on anti‐CD3‐coated plates in
the absence or presence of PGG in the final concentration 20 μM.
After 20 hr of cell culture, we observed that addition of PGG to the
splenocytes slightly reduced the percentage of CCR5+CD3+ and
CCR5+CD4+ cells. In addition, the mean intensity of fluorescence for
CCR5 was decreased within CD4+ T‐cells (Table 1). PGG also
decreased the mean intensity of fluorescence for CD25 in both
CD4+ and CD8+ T‐cells but had no effect on the expression of
hyaluronan receptor—CD44 (Table 1), confirming possible direct
effects of PGG on T‐cell biology, which were observed in vivo.
However, PGG at a dose of 50 μM had no effect on RANTES
(CCL5) mRNA expression but effectively decreased the level of
chemokine (C–C motif) ligand 2 (CCL2; also referred to as MCP‐1)
mRNA in the line of fibroblasts SW872 differentiated to adipocytes
FIGURE 3 Effect of 1,2,3,4,6‐penta‐O‐galloyl‐β‐D‐glucose (PGG) onT‐cell infiltration in perivascular adipose tissue (pVAT) and the expression of
selected genes in aorta and pVAT in Ang II‐dependent hypertension. (a) Absolute number of CD4+ and CD8+ T‐cells bearing CCR5, CD25, and
CD44 in pVAT expressed as cells·mg−1 of tissue (n = 7 each). (b) Expression of MCP‐1 (CCL2), MIP‐1α (CCL3), MIP‐1β (CCL4), and RANTES (CCL5)
in aorta and pVAT of sham and Ang II groups treated with PGG or placebo (n = 5 for sham and n = 6 for Ang II). *P < 0.05
MIKOLAJCZYK ET AL. 1957BJP(Figure S4a,b), suggesting that the mechanism of this anti‐
inflammatory effect is more complex.
3.4 | PGG inhibits chemokine expression in vivo
Next, we investigated the effect of PGG on chemokine expression in a
mouse model of experimental hypertension. Fourteen days of administra-
tion of Ang II significantly increased the expression of MCP‐1 and
RANTES in both aorta and pVAT (Figure 3b). We also observed increased
expression of macrophage inflammatory protein 1 α (MIP‐1α; also known
as CCL3) in pVAT following Ang II infusion (Figure 3b). Interestingly, the
administration of PGG significantly decreased the expression of both
MCP‐1 in aorta and RANTES in pVAT (Figure 3b) while not exerting sta-
tistically significant effects on the expression of MIP‐1α and MIP‐1β (also
known as CCL4; Figure 3b).3.5 | Effect of PGG on T‐cell cytokine production
Considering the ability of PGG to decrease the expression of some cell
activation markers, we next investigated its effect on the production
of cytokines by T‐cells. Addition of PGG to T‐cells 30 min prior to
stimulation had no effect on the content of CD4+TNF+, CD8+TNF+,
and CD3+CD4−CD8–TNF+ T‐cells (Figure 4a). Using SW872 humanfibroblasts differentiated to adipocytes, we have observed no effect
of PGG on mRNA encoding TNF expression (Figure S4c). PGG
decreased the content of IFN‐γ positive cells, and this effect was par-
ticularly seen within CD8+ and CD3+CD4−CD8− T‐cells (Figure 4b).
PGG had no effect on the content of CD4+IFN‐γ+ cells (Figure 4b).
PGG administration during stimulation of T‐cells with leukocyte acti-
vating cocktail decreased the content of IL‐17A positive CD4+ as well
as CD3+CD4−CD8– cells, but this effect was statistically significant
only in relation to double negative (CD3+CD4−CD8−) T‐cells
(Figure 4c). Additional performed experiments confirmed that PGG in
a final concentration of 20 μM did not affect, to a significant degree,
the percentage of dead cells in T‐cell culture (data not shown).
3.6 | Effect of PGG on T‐cell cytokine production in
Ang II‐dependent hypertension
Next, we examined the effect of PGG on cytokine production by
T‐cells isolated from pVAT from sham‐ and Ang II‐treated mice.
Chronic Ang II administration increased the number of CD4+TNF+,
CD8+TNF+, and CD3+CD4−CD8−TNF+ T‐cells in either PGG‐treated
or placebo group (Figure 5a). Interestingly, an i.p. administration of
PGG (every 2 days) starting 1 week before minipump implantation
and throughout the Ang II infusion significantly reduced the number
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1958 MIKOLAJCZYK ET AL.BJPof CD8+TNF+ cells but had no effect on CD4+TNF+ and
CD3+CD4−CD8−TNF+ T‐cells (Figure 5a). Ang II administration signifi-
cantly increased the number of CD8+IFN‐γ+ T‐cells, and PGG adminis-
tration decreased the content of these cells (Figure 5b).
Ang II infusion increased the content of CD4+IL‐17A+ and
CD3+CD4−CD8−IL‐17A+ T‐cells. This effect was not observed in the
group treated with PGG. Interestingly, the administration of PGG
significantly reduced the content of IL‐17A positive CD4+ as well as
CD3+CD4−CD8− T‐cells (Figure 5c).3.7 | Effect of PGG on vascular dysfunction and BP
elevation in response to Ang II
We next investigated the effect of PGG on vascular function, ROS
production, and BP regulation in the context of alterations to inflam-
matory processes previously linked to hypertensive pathology.
Importantly, PGG partially prevented development of endothelial
dysfunction evoked by Ang II‐induced hypertension (Figure 6a), while
endothelium‐independent responses to SNP were not altered
(Figure 6b). In line with this, PGG prevented vascular oxidative stress
as measured by lucigenin‐enhanced chemiluminescence in aortic rings
(Figure 6c). Interestingly, these changes were independent of BP
regulation as Ang II increased BP to the same extent in both
placebo‐treated and PGG‐treated mice (Figure 6d).4 | DISCUSSION
As we are learning about the potential benefits of limiting vascular inflam-
mation (Kusters et al., 2018; Ridker et al., 2017), there is an urgent need to
identify novel ways to target vascular inflammation and investigate their
effects on cardiovascular parameters. PGG represents a promising candi-
date in the prevention and therapy of many inflammatory diseases, diabe-
tes, and cancer (Zhang et al., 2009). While numerous studies have focused
on its antitumour activity in a number of pathologies, primarily through
the induction of apoptosis of cancer cells, several key papers have sug-
gested significant anti‐inflammatory properties of PGG (Feldman et al.,
2001; Kang et al., 2005; Kiss, Filipek, Zyzynska‐Granica, & Naruszewicz,
2013; Wu & Gu, 2009). In the present study, we focused on specific
effects of PGG on vascular inflammation, showing that it affects, in partic-
ular, cellular components of the inflammatory infiltrate and may also
inhibit T‐cell activation and recruitment to the vessel wall. This is impor-
tant in the prevention of vascular damage as a consequence of hyperten-
sion, which we have used as a model system of vascular inflammation. In
preliminary experiments, we observed that PGG decreased the number of
T‐cells in pVAT while having only a moderate effect on macrophages. For
this reason, we have focused on characterization of T‐cell subsets in more
details. In addition, this direction of study follows our previous investiga-
tions showing the effect on T‐cells on vascular function in hypertension
(Mikolajczyk et al., 2016), while macrophages were demonstrated to be
more important in models of atherosclerosis (Skiba et al., 2017).
Our studies are in line with previous reports of systemic anti‐
inflammatory activity of PGG, which suppresses a number of pro‐
FIGURE 4 Effect of 1,2,3,4,6‐penta‐O‐galloyl‐β‐D‐glucose (PGG) on cytokine production by T‐cells. Freshly isolated splenocytes were stimulated
with leukocyte activating cocktail and were cultured in the presence of PGG (final concentration 20 μM) for 4 hr. After this time, intracellular
expressions of (a) TNF, (b) IFN‐γ, and (c) IL‐17A within (a–c) CD4+, (a, b) CD8+, and (a–c) CD3+CD4−CD8− were assessed by flow cytometry.
Average values + SEM and representative flow cytometric examples are shown (n = 6). *P < 0.05
MIKOLAJCZYK ET AL. 1959BJPinflammatory cytokines (such as TNF‐α) from human peripheral blood
mononuclear cells exposed to LPS (Feldman et al., 2001). Through the
suppression of TNF‐α, PGG effectively protects from otherwise
lethal doses of LPS challenge (Genfa et al., 2005). PGG significantly
reduced LPS‐induced NO production in macrophages, decreased
gene expression and production of iNOS in a dose‐dependent
manner (Kim et al., 2009; Lee, Lee, & Mar, 2003), and inhibited
COX‐2 activity in LPS‐activated macrophages (Lee et al., 2003) as
well as the activation of NF‐κB (Kim et al., 2009). In addition,
PGG, inhibited gene expression and secretion of IL‐8, a major medi-
ator of acute neutrophil‐mediated inflammation, and CCL‐2, a major
mediator of chronic macrophage‐mediated inflammation in human
monocytic U937 cells stimulated with phorbol myristate acetate
(Oh et al., 2003).
However, no studies to date have addressed the effect of this
compound on vascular inflammation and cytokine production, particu-
larly essential for the regulation of endothelial function. We have
recently shown that IFN‐γ produced by CD8 cells infiltrating pVAT
appears to be particularly important in the regulation of vascular func-
tion in hypertension (Kossmann et al., 2013; Mikolajczyk et al., 2016).
This is essential because endothelial dysfunction precedesdevelopment of atherosclerosis and leads to the clinical complications
of hypertension (Wilk et al., 2013).
In the present study, we show for the first time that 20 μM of PGG
suppressed PMA‐ and calcium ionophore‐induced release of IFN‐γ
from both CD8+ and CD3+CD4−CD8− cells.
Interestingly, while PGG administration affected a variety of
immune cells and pro‐inflammatory mechanisms, there was a marked
decrease in the production of IFN‐γ in CD8+ T‐cells upon Ang II infu-
sion in comparison to the same group treated with placebo.
While PGG supressed other markers of T‐cell activation, it did not
induce cell death in the examined T‐cells.
Our findings are in line with recent studies by Kim et al. (2015)
who observed that p.o. administration of PGG suppressed the produc-
tion of T helper 2 (IL‐4 and IL‐13) and T helper 1 (IFN‐γ) as well as pro‐
inflammatory cytokines such TNF‐α and IL‐6. However, this was not
observed in the case of anti‐inflammatory IL‐10 in ovalbumin‐
restimulated splenocytes from ovalbumin‐sensitized mice.
Interestingly, PGG selectively induced IL‐10 production in serum
related to regulatory T‐cells (Kim et al., 2015). Effects of PGG on mac-
rophages are better characterized. PGG has been shown to suppress
IL‐1β, TNF‐α, and IL‐6 in LPS‐stimulated peritoneal macrophages
FIGURE 5 Effect of 1,2,3,4,6‐penta‐O‐galloyl‐β‐D‐glucose (PGG) on cytokine production by T‐cells during Ang II‐dependent hypertension.
Leukocytes isolated from perivascular adipose tissue of sham‐ and Ang II‐infused mice treated with PGG or placebo were stimulated with
leukocyte‐activating cocktail and were cultured for 4 hr. After this time, intracellular expressions of (a) TNF, (b) IFN‐γ, and (c) IL‐17A within (a–c)
CD4+, (a, b) CD8+, and (a–c) CD3+CD4−CD8− were assessed by flow cytometry. Average values + SEM and representative flow cytometric
examples for Ang II‐treated with PGG or placebo are shown (n = 5 for sham and n = 6–7 for Ang II). *P < 0.05
1960 MIKOLAJCZYK ET AL.BJPwhile increasing expression of the anti‐inflammatory cytokine IL‐10.
This effect was mediated by suppression of NF‐κB and MAPK
signalling pathways in a MyD88 adaptor protein‐dependent manner
(Jang, Hyam, Jeong, Han, & Kim, 2013).
Although we did not observe a decreased in vitro production of
TNF‐α after PGG administration in neither T‐cells nor SW872‐derived
adipocytes, such an effect was evident in response to in vivo
administration of PGG. PGG significantly reduced the number of
CD8+TNF+ cells but had no effect on the content of CD4+TNF+ and
CD3+CD4−CD8−TNF+ T‐cells.
Previous studies have demonstrated an essential role of IL‐17 in
hypertensive vascular dysfunction (Madhur et al., 2010); (Saleh,
Norlander, & Madhur, 2016). Therefore, we investigated the effects
of PGG on the expression of this cytokine upon activation. While we
observed the suppression of IL‐17 production across all T‐cell subsets
in vitro, it reached statistical significance only in CD3+CD4−CD8− cells,
which is in line with the fact that these cells are the predominantsource of IL‐17 in hypertension (Caillon et al., 2017; Saleh et al.,
2016). In vivo study using an experimental model of Ang II‐dependent
hypertension confirmed that PGG also effectively inhibited the pro-
duction of IL‐17A by CD4+ and CD3+CD4−CD8− T‐cell subsets. Inter-
estingly, while we observed a number of vasoprotective effects in
relation to vascular inflammation, endothelial dysfunction, and vascu-
lar oxidative stress, these effects were independent of BP regulation,
as i.p. injection of PGG at a dose of 10 mg·kg−1 every 2 days did not
attenuate Ang II‐induced hypertension. There was, however, a modest
trend towards a mild BP reduction in these mice. It is also important to
note that we have only performed tail‐cuff BP measurement, and the
use of telemetry could result in a more sensitive effect. Lack of antihy-
pertensive effect may also be linked to the model we used. Interest-
ingly, PGG revealed a strong dose‐dependent hypotensive effect,
reducing the BP significantly in spontaneously hypertensive rats with
infusion of angiotensin I (Liu et al., 2003). However, in that study,
the authors used a complex model of spontaneous hypertension
FIGURE 6 Effect of 1,2,3,4,6‐penta‐O‐galloyl‐β‐D‐glucose (PGG) on Ang II‐dependent hypertension and regulation of vascular dysfunction.
(a) Effect of PGG on endothelium‐dependent vasodilatation to ACh in aortas of mice infused with Ang II (n = 7 for sham and n = 10 for Ang II).
(b) Endothelium independent vasodilatation shown as relaxations to sodium nitroprusside after administration of PGG (n = 7 for sham and n = 10
for Ang II). Statistical analysis was performed by repeated‐measures ANOVA. (c) Aortic superoxide production measured by lucigenin‐enhanced
chemiluminescence (5 μM) in mice infused for 14 days with buffer (sham) or Ang II and treated with PGG or placebo (n = 12 each group). (d) Mean
daily values of non‐invasive BP measurements by tail‐cuff plethysmography during Ang II infusion in mice treated with PGG or placebo (n = 6 each
group). *P < 0.05
MIKOLAJCZYK ET AL. 1961BJP(through the use of spontaneously hypertensive rats), which is more
sophisticated than the model of Ang II‐induced hypertension (Lin,
Lee, Chan, & Tse, 2016; Liu et al., 2003). It should be emphasized that
in that study, the authors also investigated the acute effect of PGG
preceded by an infusion of Ang I. In contrast, we focused on the
chronic effects of PGG, which did not reduce BP response to Ang II
in our study.
ROS plays an important role in the regulation of endothelial func-
tion (Radziwon‐Balicka et al., 2017; Shafique et al., 2017; Tsai et al.,
2017). It is well known that PGG acts as a ROS scavenger (Viswanatha,
Shylaja, & Mohan, 2013). Moreover, recently published studies have
revealed that PGG induced SOD activity in Caenorhabditis elegans
and reduced intracellular ROS accumulation in a dose‐dependent
manner (Ahn et al., 2013). Early studies on PGG have demonstrated
that it can protect cells from oxidative stress via heme oxygenase‐1
induction, indicating that the PGG can also act as an indirect antioxi-
dant (Choi et al., 2002). The effects of PGG on vascular function
are important. Although they may be partially linked to the reduction
of vascular inflammation, PGG may also have direct effects on the
vasculature. Indeed, we observed a significant reduction of vascular
oxidative stress by PGG, in line with the fact that tannins have antiox-
idant properties (Riedl & Hagerman, 2001; Viswanatha et al., 2013)
in a number of cellular models (Abdelwahed et al., 2007; Okubo
et al., 2000).
It is likely that the effects on endothelial function are mediated in
part by the direct antioxidant properties of PGG, leading to an
increase of NO bioavailability and in part indirectly, by reducingperivascular inflammation. The latter mechanism is supported by our
previous study showing that perivascular T‐cell infiltration may
stimulate both oxidative stress and endothelial function (Mikolajczyk
et al., 2016). In that study, we demonstrated that IFN‐γ was pivotal
in the induction of endothelial dysfunction (Mikolajczyk et al., 2016).
Interestingly, PGG affected T‐cell IFN‐γ production to the largest
extent in the present in vivo study. This possible pleiotropic effect
may indicate that compounds such as PGG may target multiple mech-
anisms of vascular dysfunction and disease, which could make
them particularly valuable in multifactorial diseases such as hyperten-
sion. We observed that PGG normalized ROS production but only
modestly improved vascular function. However, in our study, we used
lucigenin‐enhanced chemiluminescence, which allows detection of
superoxide anion production. It is known that other radicals (hydroxyl
radical, lipid peroxyl radical, and alkoxyl radical) and other molecules
including peroxynitrite, hypochlorous acid, and hydrogen peroxide
have strong oxidant properties and can affect vascular function
(Guzik et al., 2002). Furthermore, Ang II and H2O2 cause the
phosphorylation of eNOS on Tyr657, attenuating NO production
(Carnicer et al., 2017; Douglas et al., 2018; Loot, Schreiber, Fisslthaler,
& Fleming, 2009). Finally, Ang II could cause an H4B deficiency leading
to eNOS uncoupling, resulting in lower NO production. All factors
mentioned above are likely to work in concert, leading to the impair-
ment of endothelium‐dependent vasodilatation in hypertensive
animals.
We observed that in response to SNP, there was a rightward shift
in Ang II‐treated aortas. This was seen in both PGG and placebo
1962 MIKOLAJCZYK ET AL.BJPgroups. This phenomenon is common in vascular studies of aortas
from Ang II‐infused animals and was observed previously by our group
as well as others (Itani et al., 2016; Madhur et al., 2010; Mikolajczyk
et al., 2016; Siedlinski et al., 2017) and may be linked to the impaired
sensitivity of vascular smooth muscle cells and soluble guanylyl
cyclase to NO upon chronic Ang II infusion (Sorop et al., 2017). Reduc-
tion of vascular oxidative stress and endothelial dysfunction may serve
as important mechanisms in the reduction of vascular inflammation as
both chemokines and adhesion molecules are redox sensitive. Indeed,
in a recent study, PGG was shown to inhibit a number of pro‐
inflammatory mediators such as LTB4, IL‐8, and myeloperoxidase in
human neutrophils through the suppression of ROS, particularly O2
−
(Kiss et al., 2010). PGG is also known to inhibit β2‐integrin (CD11b)
and L‐selectin (CD62L) expression on leukocytes (Kiss et al., 2013).
Our findings support and extend these observations, showing reduced
expression of molecules critical for the development of perivascular
inflammation including CCR5 and CD44. This resulted in significantly
decreased total leukocyte and T‐cell infiltration in pVAT.
Experiments performed by our group on a human line of SW872
fibroblasts differentiated to adipocytes revealed that PGG at a dose
of 50 μM effectively decreased the level of CCL‐2 mRNA while having
no effect on RANTES expression. However, the administration of PGG
decreased RANTES mRNA level in pVAT during Ang II‐dependent
hypertension, which could be associated with decreased T‐cells and
infiltration by their subsets (especially CD4+CCR5+ and CD8+CCR5+)
into the pVAT. We also observed decreased expression of MCP‐1
after PGG treatment in Ang II‐infused aorta, but this effect was not
seen in pVAT. This finding can be related to the moderate effect of
PGG on macrophage contents in pVAT. While we have only focused
on a limited number of mechanisms known to be particularly linked
to hypertensive vascular dysfunction, Kang et al. (2005) have previ-
ously shown that PGG suppresses the expression of adhesion mole-
cules such as endothelial intracellular cell adhesion molecule‐1 and
vascular cell adhesion molecule‐1 induced by TNF‐α in concert with
reduced CCL‐2 expression.
In summary, our results suggest that PGG is an important candi-
date for targeting vascular inflammation through both vascular effects
(protection from vascular oxidative stress and endothelial dysfunction)
and direct effects on T‐cell activation and their perivascular
recruitment. Thus, PGG, may provide opportunities for the effective
treatment of hypertension.ACKNOWLEDGEMENTS
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